Pharmacoeconomic evaluation of baritinib in the treatment of adult patient with moderate to severe rheumatoid arthritis with intolerance or lack of an adequate response to treatment with one or more basic antirheumatic drugs in the Russian Federation
Details
The content you want is available to Zendy users.Already have an account? Click here. to sign in.